How many insider trades does FilingIQ track for ORKA?

FilingIQ tracks 76 Form 4 insider transactions for ORKA (Oruka Therapeutics, Inc.), covering filings from Sep 11, 2024 onwards. 37 of those were filed in the last 90 days.

Are ORKA insiders net buyers or net sellers?

Across the full Form 4 history for ORKA, 5 transactions (7%) were open-market purchases and 30 (39%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ORKA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ORKA in?

Oruka Therapeutics, Inc. (ORKA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.58B.

ORKA insider trading

Healthcare

Oruka Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

7% / 39%

Market cap

$1.58B

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Company website: orukatx.com

ORKA insider activity at a glance

FilingIQ has scored 76 insider transactions for ORKA since Sep 11, 2024. The most recent filing in our index is dated May 1, 2026.

Across the full history, 5 open-market purchases and 30 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ORKA insider trades is 53.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ORKA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding ORKA

Avoro Capital Advisors LLC

$40.41M · 0.4% of AUM

Frequently asked

How many insider trades does FilingIQ track for ORKA?: FilingIQ tracks 76 Form 4 insider transactions for ORKA (Oruka Therapeutics, Inc.), covering filings from Sep 11, 2024 onwards. 37 of those were filed in the last 90 days.
Are ORKA insiders net buyers or net sellers?: Across the full Form 4 history for ORKA, 5 transactions (7%) were open-market purchases and 30 (39%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ORKA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ORKA in?: Oruka Therapeutics, Inc. (ORKA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.58B.

Methodology & sources

Every ORKA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.